Theranexus
Clinical-stage biopharmaceutical company developing treatments for rare neurological disorders.
ALTHX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013286259
- LEI:
- 969500BFCV6IC7MFQP20
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://www.theranexus.com/en/
- Sector:
- Manufacturing
Description
THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-17 18:15 |
THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON
|
English | 212.3 KB | ||
| 2024-12-17 18:15 |
THERANEXUS FAIT UN POINT SUR SA POSITION DE TRÉSORERIE ET SON HORIZON DE FINANC…
|
French | 230.9 KB | ||
| 2024-12-17 18:00 |
THERANEXUS ET EXELTIS (INSUD PHARMA) ANNONCENT UN ACCORD DE LICENCE POUR LA COM…
|
French | 178.0 KB | ||
| 2024-12-17 18:00 |
THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE LICENSING AGREEMENT TO COMMERCIA…
|
English | 177.4 KB | ||
| 2024-11-19 18:00 |
Update on the Theranexus' Batten-1 project in CLN3 Batten's disease
|
English | 323.5 KB | ||
| 2024-11-19 18:00 |
Theranexus fait le point sur son programme Batten-1 dans la maladie de Batten C…
|
French | 327.1 KB | ||
| 2024-10-23 18:00 |
THERANEXUS ANNOUNCES ITS CASH POSITION AS OF SEPTEMBER 30, 2024
|
English | 245.6 KB | ||
| 2024-10-23 18:00 |
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2024
|
French | 249.3 KB | ||
| 2024-10-17 18:00 |
THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIA…
|
English | 542.3 KB | ||
| 2024-10-17 18:00 |
THERANEXUS S'ASSOCIE À SYNERLAB POUR PRÉPARER LA COMMERCIALISATION DE SA FORMUL…
|
French | 414.2 KB | ||
| 2024-09-26 19:00 |
Rapport semestriel 1er semestre 2024
|
French | 9.7 MB | ||
| 2024-09-26 18:00 |
THERANEXUS ANNOUNCES FIRST HALF 2024 FINANCIAL RESULTS
|
English | 432.5 KB | ||
| 2024-09-26 18:00 |
THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2024
|
French | 315.3 KB | ||
| 2024-07-11 18:45 |
Theranexus publishes its cash position as of 30 June 2024 and presents an updat…
|
English | 461.1 KB | ||
| 2024-07-11 18:45 |
Theranexus publie sa trésorerie au 30 juin 2024 et fait le point sur l'avanceme…
|
French | 355.3 KB |
Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Theranexus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Theranexus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
